August 4, 2020
JCR Pharmaceuticals said on July 31 that the Pharmaceuticals and Medical Devices Agency (PMDA) has completed a review of the PI/II clinical trial notification for the company’s investigational enzyme preparation JR-171 for the treatment of mucopolysaccharidosis type 1 (MPS I)...read more